
AML Risk Stratification Gene Panel







The AML risk stratification gene panel by Next-Generation Sequencing (NGS) is a groundbreaking tool in the field of acute myeloid leukemia (AML) diagnosis and treatment. This gene panel utilizes the power of NGS technology to analyze a comprehensive set of genes associated with AML, enabling a more accurate and detailed assessment of a patient's risk profile. By examining specific genetic mutations and alterations, the panel allows for precise identification of high-risk AML patients who may require more aggressive treatment strategies. It also helps in predicting treatment response and relapse likelihood, aiding in personalized therapeutic approaches.
Note: Genetic counseling can be provided. If interested, please send the request to this email id:[email protected]







Understanding AML Risk Stratification Gene Panel
.





Other tests
- CBC (Complete Blood Count)
- FBS (Fasting Blood Sugar)
- Thyroid Profile Total (T3, T4 & TSH)
- HbA1c (Glycosylated Hemoglobin)
- PPBS (Postprandial Blood Sugar)
- Lipid Profile
- Vitamin D (25-Hydroxy)
- Urine R/M (Urine Routine & Microscopy)
- Coronavirus Covid -19 test- RT PCR
- LFT (Liver Function Test)
- KFT (Kidney Function Test)
- TSH (Thyroid Stimulating Hormone) Ultrasensitive
- ESR (Erythrocyte Sedimentation Rate)
- Uric Acid, Serum
- Vitamin B12
- CRP (C-Reactive Protein), Quantitative
- Urine C/S (Urine Culture and Sensitivity)
- Serum Electrolytes
- Serum Calcium
- Serum Creatinine
- Diabetes Screening (HbA1C & Fasting Sugar)
- KFT with Electrolytes (Kidney Function Test with Electrolytes)
- Cholesterol - Total
- Hb (Hemoglobin)
- Complete Hemogram (CBC & ESR)














